Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
収録刊行物
-
- The Lancet Gastroenterology & Hepatology
-
The Lancet Gastroenterology & Hepatology 8 (2), 133-144, 2023-02
Elsevier BV